Oct 13, 2020
0 0

Johnson & Johnson Suspends COVID-19 Vaccine Trials Due To Participant Illness

The American company Johnson & Johnson has suspended Phase III clinical trials of a coronavirus vaccine due to an "unexplained illness" of a volunteer. It was planned that 60,000 people on three continents will take part in the drug trials.

“We have temporarily suspended administration of the drug in all of our clinical trials candidates for the COVID-19 vaccine due to an unexplained illness in one of the participants. It is now being tested and assessed in accordance with our guidelines, ”Johnson & Johnson said in a statement.

The company does not indicate what symptoms the volunteer developed, referring to the confidentiality of personal data. It is not yet known whether this person received the vaccine or placebo. An investigation is underway with the involvement of independent experts.

The start of a phase III clinical trial of the vaccine involving 60,000 participants on three continents was announced by the American pharmaceutical giant on September 23. The candidate vaccine is based on the AdVac® technology platform, which has already been used to develop vaccines against Ebola, Zika, RSV and HIV.

In September, the Anglo-Swedish company AstraZeneca announced the suspension of large-scale tests. Western media disseminated information that after the administration of the drug, the volunteer was diagnosed with transverse myelitis - an inflammatory syndrome that affects the spinal cord. An independent investigation was carried out over several days, during which it was required to establish whether the disease was a side effect of the vaccine. On September 12, tests were resumed, data on the patient's health were not disclosed.

Article Categories:

Leave a Reply